Abstract
Kidney disease(KD) is a major challenge for global public healthcare systems. Traditional biomarkers (such as serum creatinine and urea) for measuring kidney function are not sufficient sensitivity and specificity. They are not only affected by many factors, but also were only increase significantly in severe KD. Therefore, more sensitive biomarkers for evaluation of KD is essential. Metabolomics is a promising tool that identify non-targeted, global small-molecule metabolite profiles of complex samples, such as biofluids and tissues extract. The application of metabolomics in KD studies has developed rapidly in the past years. Many benefits have been shown from the use of metabolomics in identifying biomarkers for KD. In particular, metabolomic approaches have the potential to diagnose KD with a higher accuracy than traditional diagnostic methods. Metabolomics in KD research has been expanded from experimental study into clinical applications.(Chin J Lab Med, 2018, 41: 246-250) Key words: Kidney disease; Biomarker; Metabonome/metabolome; Metabonomics/metabolomics
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
